4.0 Review

How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective

Journal

Publisher

SPRINGER FRANCE
DOI: 10.1007/s13318-019-00598-0

Keywords

-

Funding

  1. National Natural Science Foundation of China [81573505]
  2. 'Weak Discipline Construction Project' of Shanghai Municipal Commission of Health and Family Planning [2016ZB0301-01]

Ask authors/readers for more resources

Delayed or missed doses are unavoidable in clinical practice and remain as a challenge that threatens a patient's health and quality-of-life, especially in the pharmacotherapy of chronic disease treatment. Unfortunately, information or guidance concerning the management of delayed or missed doses is scarce, precluding clinicians or clinical pharmacologists from instructing patients in a precision dosing manner. It is therefore urgent to develop remedial strategies to inform patients of alternative dosing regimens in compensation for the loss of efficacy due to delayed or missed doses and minimize unintended clinical consequences. Studies aiming to establish remedial regimens have been conducted since the 1980s for oral contraceptives and antihypertensive agents, using the controlled substitution of placebos for active medications. However, it appeared to be unethical in many areas of pharmacotherapy due to deliberately discontinuing or restarting the medication. Alternatively, pharmacometric modeling and simulation offers an opportunity to investigate the effect of various non-adherence scenarios on pharmacokinetic profiles and establish the optimum remedial dosing regimen in a time-effective and systematical way. This review provides a general overview of procedures and strategies on how to develop remedial dosing regimens based on pharmacometric approaches through the scrutiny of case examples in the literature.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy

Yi-wei Yin, Xiao-qin Liu, Jia-qin Gu, Zi-ran Li, Zheng Jiao

Summary: This study aimed to explore appropriate remedial dosing regimens for non-adherent edoxaban-treated NVAF patients through Monte Carlo simulation. The proposed remedial strategies differed from the current recommendations and were related to the delay time. PK/PD modelling and simulation are effective in developing and evaluating the remedial strategies of edoxaban.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Pharmacology & Pharmacy

Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach

Yueting Chen, Yang Yang, Shansen Xu, Chenyu Wang, Pan Shu, Xiaoyu Zhang, Qin Huang, Jin Sook Kim, Zheng Jiao

Summary: This study aimed to develop population pharmacokinetics and pharmacodynamics (popPK/PD) models of SIM0295 and explore potential covariates to inform clinical drug development. SIM0295 pharmacokinetics was described using a two-compartment model with the absorption of four transit compartments and first-order elimination. The established popPK/PD model characterized the dose-exposure-response relationship for SIM0295 in healthy subjects and patients with gout and hyperuricemia and could be used to inform the drug development.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)

Review Pharmacology & Pharmacy

Parametric population pharmacokinetics of isoniazid: a systematic review

Jinmeng Li, Xinjun Cai, Yueting Chen, Chenyu Wang, Zheng Jiao

Summary: Isoniazid (INH) plays a vital role in tuberculosis (TB) prevention and treatment, but there are significant pharmacokinetic variations in patients receiving standard dosages. This review explores the population pharmacokinetic studies of INH and identifies significant covariates that affect INH pharmacokinetics. The findings suggest that fast metabolizers require a higher daily dose of INH compared to slow metabolizers, and pediatric patients need a higher dose per kilogram than adults. Further pharmacokinetic studies are needed to accurately adjust the dosage for anti-tuberculosis drugs.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies

Jue-Hui Mao, Lu Han, Xiao-Qin Liu, Zheng Jiao

Summary: This review provides an overview of published population pharmacokinetic studies on olanzapine and explores factors contributing to its pharmacokinetic variability. The results showed that the apparent clearance in adults was 0.253 L/h/kg, 27-43% lower than in infants and children. Men and smokers had higher apparent clearance, increasing it by 32% and 34% respectively. Furthermore, further population studies are needed to clarify the dose-exposure-response relationship of olanzapine.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban

Xiao-Qin Liu, Zi-Ran Li, Chen-Yu Wang, Yue-Ting Chen, Zheng Jiao

Summary: This review investigated the potential ethnic differences in the pharmacokinetic and pharmacodynamic characteristics of rivaroxaban between Asians and Caucasians. The findings suggest that Asians may require a lower dose of rivaroxaban compared to Caucasians. Further studies are needed to confirm this ethnic difference and optimize dosing regimens.

PHARMACEUTICS (2023)

Article Health Care Sciences & Services

Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation

Yi-Fan Cui, Yan Pan, Min-Fang Zhu, Zheng Jiao

Summary: This study aimed to investigate the pharmacokinetics of tacrolimus and the influential factors in Chinese patients after lung transplantation. The results showed a significant correlation between CYP3A5*3 genetic polymorphisms and the pharmacokinetics of tacrolimus.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Letter Medicine, General & Internal

Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody-drug conjugates

Dan -Na Wu, Ai-Jia Guan, Guo-Fu Li

ECLINICALMEDICINE (2023)

Editorial Material Pharmacology & Pharmacy

Use of Clearance Concepts to Simulate Impact of Interleukin-6 on Drug Elimination Governed by Cytochromes P450 3A4 and Glomerular Filtration Rate

Xiang Chen, Guo Yu, Guo-Fu Li

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2023)

Article Pharmacology & Pharmacy

Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis

Zhe Tang, Jing Guan, Jue-hui Mao, Lu Han, Juan-juan Zhang, Rui Chen, Zheng Jiao

Summary: This study quantitatively evaluated and compared the effects of oral contraceptives, insulin sensitizers, and antiandrogens for treating polycystic ovary syndrome. The results showed that oral contraceptives performed well in improving menstruation, hirsutism score, and free androgen index, but elevated triglyceride levels. Metformin had a slight BMI-lowering effect, and lifestyle intervention with placebo significantly decreased BMI. Antiandrogens had weaker effects in reducing hirsutism score and free androgen index compared to oral contraceptives. Individualized pharmacotherapies based on baseline measurements achieved more clinical improvements. Further research is needed on long-term risk-benefit profiles and emerging therapies.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2023)

Article Infectious Diseases

External evaluation of the predictive performance of published population pharmacokinetic models of linezolid in adult patients

Yan Qin, Zheng Jiao, Yan-Rong Ye, Yun Shen, Zhe Chen, Yue-Ting Chen, Xiao-Yu Li, Qian-Zhou Lv

Summary: This study aimed to evaluate the predictive performance of published pharmacokinetic models of linezolid in adult patients. The results showed that these models exhibited insufficient predictive ability, indicating the necessity of incorporating therapeutic drug monitoring of linezolid in clinical applications.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2023)

No Data Available